SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop CRISPR-Based Treatment for FSHD
06/08/25, 11:50 PM
Location
san diegoIndustry
non profit
biotechnology
health care
Type
partnership
SOLVE FSHD and Modalis Therapeutics Corporation have initiated a strategic partnership aimed at developing an innovative CRISPR-based therapy for facioscapulohumeral muscular dystrophy (FSHD). The collaboration focuses on leveraging Modalis's proprietary technology to create a novel therapeutic solution to suppress the disease-causing DUX4 gene.
Company Info
Location
san diego, california, united states
Additional Info
September 13, 2022 09:05 AM Eastern Daylight TimeSAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today announced that Solve FSHD has provided one million dollars in support of n-Lorem’s efforts to fully understand the complex molecular cause of facioscapulohumeral muscular dystrophy-2 (FSHD2). Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Nano-Rare DiseaseWatch: n-Lorem Foundation: Creating a Better Future for Nano-Rare, One Patient at a TimeSOLVE FSHDSolve FSHD is a Vancouver-based venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for facioscapulohumeral muscular dystrophy (FSHD).